Histidine-Tryptophan-Ketoglutarate Solution Versus Blood Cardioplegia in CABG
Summary
Background: In cardiac surgery, myocardial protection is mandatory during cross clamp time followed by reperfusion. Use of cardioplegic solutions preserves myocardial energy stores, hindering electrolyte disturbances and acidosis during periods of myocardial ischemia. This study was designed to compare the efficacy and safety of Histidine-tryptophan-ketoglutarate (HTK) solution versus blood cardioplegia in coronary artery bypass graft surgery. Methods: Three hundred and twenty patients were randomized into Histidine-tryptophan-ketoglutarate (HTK) group and blood cardioplegia group. Ventilation time, total bypass time, cross clamp time, length of ICU or hospital stay and the early postoperative outcomes were analysed.
Timeline
- Start
- 2019-12-25
- Primary completion
- 2020-03-31
- Completion
- 2020-04-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | HTK cardioplegic solution | Unknown | 30 unknown | Other |
| Comparator | blood cardioplegia | Unknown | 1000 ml | Other |
Indications
No indication recorded.